$Tevogen Bio Holdings (TVGN.US)$ look what I found. It not b...
look what I found. It not bad news at all.
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
PUBLISHED
OCT 25, 2024 5:34PM EDT
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company’s proprietary ExacTcell™ technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2 (PASC).
Tevogen Bio’s recently shared forecast reflects its business plan of market entry by the end of 2026.
“The rapid and cost-effective development of TVGN 489, achieved at a fraction of industry norms, strengthens my confidence in Tevogen’s innovative business model,” remarked Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, Nobel Peace Prize nominee, inventor of ExacTcell. “The positive clinical trial underscores TVGN 489’s potential, and it is my personal commitment that the company will do everything in its power to speed up the development process. I am pleased that the company was able to make progress to bridge any information gap and look forward to sharing other achievements in the coming weeks, particularly on the progress of Tevogen.AI.”
Pipeline
TVGN 489:
Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer [part of Tevogen Bio Oncology forecast]
Treatment of SARS-CoV-2 infection in patients with other cancers [part of Tevogen Bio Oncology forecast]
SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
SARS-CoV-2 infection in patients under treatment for and psoriatic arthritis
Treatment of Long COVID [part of Tevogen Bio Specialty Care forecast]
TVGN 920: Cervical cancer prevention
TVGN 930: EBV-associated lymphomas
TVGN 960: Mouth and throat cancer
TVGN 601: Multiple sclerosis
PUBLISHED
OCT 25, 2024 5:34PM EDT
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company’s proprietary ExacTcell™ technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2 (PASC).
Tevogen Bio’s recently shared forecast reflects its business plan of market entry by the end of 2026.
“The rapid and cost-effective development of TVGN 489, achieved at a fraction of industry norms, strengthens my confidence in Tevogen’s innovative business model,” remarked Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, Nobel Peace Prize nominee, inventor of ExacTcell. “The positive clinical trial underscores TVGN 489’s potential, and it is my personal commitment that the company will do everything in its power to speed up the development process. I am pleased that the company was able to make progress to bridge any information gap and look forward to sharing other achievements in the coming weeks, particularly on the progress of Tevogen.AI.”
Pipeline
TVGN 489:
Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer [part of Tevogen Bio Oncology forecast]
Treatment of SARS-CoV-2 infection in patients with other cancers [part of Tevogen Bio Oncology forecast]
SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
SARS-CoV-2 infection in patients under treatment for and psoriatic arthritis
Treatment of Long COVID [part of Tevogen Bio Specialty Care forecast]
TVGN 920: Cervical cancer prevention
TVGN 930: EBV-associated lymphomas
TVGN 960: Mouth and throat cancer
TVGN 601: Multiple sclerosis
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Daily Investors : Chicago Indiana
MrSuperStonk : its not bad news. Its just the time frame. It will take a dump on monday and yes it will recover over a few months. But this will not jump to 5 has we touth it would